Navigation Links
Syndax Pharmaceuticals Appoints Arlene Morris as CEO
Date:4/18/2012

WALTHAM, Mass., April 18, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., an oncology company moving into phase 3 having completed randomized, placebo controlled phase 2 studies, announced the appointment of Arlene M. Morris as chief executive officer.  Joanna Horobin, MD will serve as president. 

"Syndax is leading the field of epigenetics—a novel way to control gene regulation—to address unmet needs in cancer due to the problem of resistance," said Dennis Podlesak, chairman of the Syndax board of directors. "With the positive phase 2 randomized, placebo-controlled data and the addition of Arlene Morris to our impressive leadership team, Syndax is well positioned to successfully complete the final phase of clinical development to achieve our goal of providing a new treatment option for women with metastatic breast cancer."

During her eight years as president and CEO at Affymax, Ms. Morris led the company through the development of peginesatide (Omontys®), a strategic collaboration with Takeda and an Initial Public Offering. Prior to Affymax Ms. Morris was the president and CEO of Clearview Projects, an advisory firm which counseled biopharmaceutical and biotechnology companies on strategic transactions. Before that she was the senior vice president, business development at Coulter, a biotechnology company focused on immunotherapeutic approaches to cancer, autoimmune and infectious diseases, where she completed numerous transactions including a $1.0 billion merger between Corixa and Coulter. Ms. Morris began her career at Johnson & Johnson (J&J) as a sales representative rising to vice president of business development. Ms. Morris received her bachelor's degree in biology and chemistry from Carlow College. In addition to Syndax Ms. Morris serves on the board of directors of Neovacs and MediciNova.

"After working with Syndax as a director over the past nine months
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
2. Syndax Pharmaceuticals to Present at Upcoming Fall Conferences
3. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
4. Syndax Pharmaceuticals to Present at BIO Investor Forum
5. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
7. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
8. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
9. Swedish Bactiguard to Enter Into an Exclusive Distribution Agreement With Cadila Pharmaceuticals
10. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
11. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN, Ireland , September 18, ... ,Research and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) ... "Biocompatible Materials - Global Strategic ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report ... Materials in US$ Million by the ...
(Date:9/18/2014)... On Tuesday, Secretary of Energy Ernest Moniz joined ... Lab Day on the Hill. The event highlighted several ... Durbin and Risch also formally launched the Senate National ... reach of the national labs as leaders in developing ... our nation's most pressing challenges. , "The national labs ...
(Date:9/18/2014)... Sept. 18, 2014 Research and ... "Global N-acetylcysteine Industry Report 2014" report ... N-acetylcysteine Industry Report 2014 is a professional and ... global N-acetylcysteine industry. The report provides ... classifications, applications and industry chain structure. The N-acetylcysteine ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) ... to their offering. The global companion ... of 22.7% from 2014 to 2019. Factors such as ... adoption of companion diagnostics by the pharmaceutical industry, support ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global N-acetylcysteine Industry Report 2014 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
...   Sigma-Aldrich Corporation (NASDAQ: ... announced it has signed an agreement to acquire BioReliance Holdings, ... Avista Capital Partners for $350 million in cash.  The acquisition ... is expected to close in the first quarter of 2012.  ...
... According to a new market research report, ... , published by MarketsandMarkets ( http://www.marketsandmarkets.com ), global seed ... protection market. This growth is fueled by government encouragement ... This growth is particularly higher in geographies such as ...
... GENEVA, Jan. 9, 2012   Selexis SA announced ... Vice President of Strategic and Market Development. ... CEO, Dr. Igor Fisch and will be responsible for ... biologics and difficult-to-express protein markets. ...
Cached Biology Technology:Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 2Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 3Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 4MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016 2MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016 3Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development 2
(Date:9/17/2014)... health care to reproductive technologies, the justice and ... of people to identify key issues, articulate their ... find the most defensible ways forward. But what ... societal conversations?, The Hastings Center and the Presidential ... teamed up to publish a series of essays ...
(Date:9/17/2014)... Fauna Europaea started in 2000 as an EC-FP5 four-year ... years of steady progress and successful participations in several ... European Biodiversity Observation Network project (EU BON), to ... the contributors and to extend the general dissemination of ... Journal has applied its novel e-Publishing tools ...
(Date:9/17/2014)... research from the Copenhagen Centre for Social Evolution and ... theory that birth weight and -length can partially predict ... such as autism and schizophrenia later in life. The ... and subsequent hospital diagnoses for up to 30 years, ... The study is published today in the Proceedings ...
Breaking Biology News(10 mins):Why bioethics literacy matters 2Why bioethics literacy matters 3Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3
... transcription the process inside the nucleus of cells by ... a large, ever-changing multiprotein complex is enlisted to assist ... an exquisitely choreographed dance, each step in the process has ... to be accurate and useful in subsequent events. These ...
... discovery by Canada-U.S. biophysicists will improve the understanding of ion ... which when they malfunction can cause genetic illnesses that attack ... As reported in the current issue of the Proceedings ... researchers from the Universit de Montral and the University of ...
... we maximise the value and use of epidemiological ... the theme of a conference being held on ... Co-organised by PHOEBE (Promoting Harmonisation of Epidemiological Biobanks), ... (Biobanking and Biomolecular Resources Research Infrastructure), the conference ...
Cached Biology News:CSHL scientists discover new way in which ubiquitin modifies transcriptional machinery 2Researchers advance knowledge of little 'nano-machines' in our body 2Harmonizing Biobank Research Conference in 2009 2Harmonizing Biobank Research Conference in 2009 3
... vaccinia virus is a type I eukaryotic ... superhelical turns (also called right- and left-handed ... of the reaction is a covalently closed, ... superhelical turns. DNA Topoisomerase I does not ...
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
...
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
Biology Products: